Sign in Subscribe
COVID-19

Comparative Analysis of Moderna's mRNA-1083 and Pfizer's Dual-Target mRNA Vaccines for Influenza and COVID-19

Strategic Insights

— 1 min read

Researchers at the University of Cambridge have conducted a comprehensive review of Moderna's mRNA-1083 and Pfizer/BioNTech's mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. The study found that both vaccines utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna's mRNA-1083 showed superior immune responses, while Pfizer's mRNA-1020/1030 performed well but was slightly less effective against influenza B.

Key Takeaways:

  • The study compared the efficacy of Moderna's mRNA-1083 and Pfizer's mRNA-1020/1030 dual-target vaccines for influenza and COVID-19.
  • Both vaccines utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles.
  • Moderna's mRNA-1083 showed superior immune responses against COVID-19, while Pfizer's mRNA-1020/1030 was less effective against influenza B.
  • The vaccines simplify immunization strategies, enhance protection, and emphasize the need for global vaccine equity to prevent future outbreaks.
  • The study highlighted the potential of mRNA vaccines in preventing future pandemics.
  • The inclusion of additional authors, such as Abiodun Adegbesan, Kolade Adegoke, and Courage Idahor, adds to the credibility and expertise of the research team.
  • The study emphasizes the importance of immunization in preventing the spread of COVID-19 and influenza.

Statistics:

  • 10(1):1-10: The journal article was published in npj Vaccines, Volume 10, Issue 1, pages 1-10.
  • 2025: The study was conducted in 2025 and published in the journal npj Vaccines.
  • 10.1038/s41541-025-01145-6: The journal article is available for free at the nature.com website with the DOI number 10.1038/s41541-025-01145-6.
  • 143: The article was published in Medical Letter on the CDC & FDA, June 15, 2025, page 143.

Sources:

  • npj Vaccines, 2025,10(1):1-10. (npj Vaccines - https://www.nature.com/npjvaccines/). The publisher for npj Vaccines is Nature Portfolio.
  • Medical Letter on the CDC & FDA. June 15, 2025; p 143.
  • NewsRx. New COVID-19 Data Have Been Reported by Researchers at University of Cambridge (Comparing Moderna's mRNA-1083 and Pfizer's dual-target mRNA vaccines for influenza and COVID-19). Medical Letter on the CDC & FDA. June 15, 2025; p 143.

Read more